Cargando…

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients

AIMS: Tacrolimus is a critical dose drug and to avoid under‐ and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug‐related toxicity occur despite whole‐blood tacrolimus pre‐dose concentrations ([Tac](blood)) being on target. Monitoring tacrolimus concentrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Francke, Marith I., Hesselink, Dennis A., Li, Yi, Koch, Birgit C.P., de Wit, Lucia E.A., van Schaik, Ron H.N., Yang, Lin, Baan, Carla C., van Gelder, Teun, de Winter, Brenda C.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056738/
https://www.ncbi.nlm.nih.gov/pubmed/33025649
http://dx.doi.org/10.1111/bcp.14585
Descripción
Sumario:AIMS: Tacrolimus is a critical dose drug and to avoid under‐ and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug‐related toxicity occur despite whole‐blood tacrolimus pre‐dose concentrations ([Tac](blood)) being on target. Monitoring tacrolimus concentrations at the target site (within peripheral blood mononuclear cells; [Tac](cells)) may better correlate with drug‐efficacy. The aim of this study was to (1) investigate the relationship between [Tac](blood) and [Tac](cells), (2) identify factors affecting the tacrolimus distribution in cells and whole‐blood, and (3) study the relationship between [Tac](cells) and clinical outcomes after kidney transplantation. METHODS: A total of 175 renal transplant recipients were prospectively followed. [Tac](blood) and [Tac](cells) were determined at Months 3, 6 and 12 post‐transplantation. Patients were genotyped for ABCB1 1199G>A and 3435C>T, CYP3A4 15389C>T, and CYP3A5 6986G>A. Data on rejection and tacrolimus‐related nephrotoxicity and post‐transplant diabetes mellitus were collected. RESULTS: Correlations between [Tac](blood) and [Tac](cells) were moderate to poor (Spearman's r = 0.31; r = 0.41; r = 0.61 at Months 3, 6 and 12, respectively). The [Tac](cells)/[Tac](blood) ratio was stable over time in most patients (median intra‐patient variability 39.0%; range 3.5%–173.2%). Age, albumin and haematocrit correlated with the [Tac](cells)/[Tac](blood) ratio. CYP3A5 and CYP3A4 genotype combined affected both dose‐corrected [Tac](blood) and [Tac](cells). ABCB1 was not significantly related to tacrolimus distribution. Neither [Tac](blood) nor [Tac](cells) correlated with clinical outcomes. CONCLUSIONS: The correlation between [Tac](blood) and [Tac](cells) is poor. Age, albumin and haematocrit correlate with the [Tac](cells)/[Tac](blood) ratio, whereas genetic variation in ABCB1, CYP3A4 and CYP3A5 do not. Neither [Tac](blood) nor [Tac](cells) correlated with clinical outcomes.